CN107073039B - 用于癌症治疗的免疫疗法 - Google Patents

用于癌症治疗的免疫疗法 Download PDF

Info

Publication number
CN107073039B
CN107073039B CN201580056026.0A CN201580056026A CN107073039B CN 107073039 B CN107073039 B CN 107073039B CN 201580056026 A CN201580056026 A CN 201580056026A CN 107073039 B CN107073039 B CN 107073039B
Authority
CN
China
Prior art keywords
cells
aml
dnts
dnt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580056026.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107073039A (zh
Inventor
张丽
J·B·李
B·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN107073039A publication Critical patent/CN107073039A/zh
Application granted granted Critical
Publication of CN107073039B publication Critical patent/CN107073039B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
CN201580056026.0A 2014-08-15 2015-08-17 用于癌症治疗的免疫疗法 Active CN107073039B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037889P 2014-08-15 2014-08-15
US62/037,889 2014-08-15
PCT/CA2015/050780 WO2016023134A1 (en) 2014-08-15 2015-08-17 Immunotherapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
CN107073039A CN107073039A (zh) 2017-08-18
CN107073039B true CN107073039B (zh) 2021-07-20

Family

ID=55303743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580056026.0A Active CN107073039B (zh) 2014-08-15 2015-08-17 用于癌症治疗的免疫疗法

Country Status (7)

Country Link
US (1) US10517937B2 (enExample)
EP (1) EP3180011B1 (enExample)
JP (1) JP6802150B2 (enExample)
CN (1) CN107073039B (enExample)
CA (1) CA2994462C (enExample)
ES (1) ES2869624T3 (enExample)
WO (1) WO2016023134A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200046768A1 (en) * 2018-08-09 2020-02-13 University Health Network Double negative t cells and pd-1 blockade for the treatment of cancer
CA3123467A1 (en) * 2018-12-19 2020-06-25 University Health Network Production and therapeutic use of off-the-shelf double negative t cells
CN115362253B (zh) * 2020-02-07 2025-11-11 大学健康网络 利用维奈托克增强t细胞的方法
CN113528434A (zh) * 2020-04-20 2021-10-22 瑞创生物技术有限公司 一种通用型供临床多次回输异体dnt细胞的高效体外扩增方法
CN117860782B (zh) * 2024-03-11 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 双阴性t细胞在制备治疗脊髓损伤的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101313061A (zh) * 2005-11-18 2008-11-26 大学健康网络 扩增双阴性t细胞的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR273760A (enExample)
US6953576B2 (en) 2000-08-21 2005-10-11 University Health Network Method of modulating tumor immunity
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CA3021226A1 (en) 2015-05-11 2016-11-17 University Health Network Method for expansion of double negative regulatory t cells
US10201572B2 (en) * 2015-09-15 2019-02-12 University Health Network Combination therapy with double negative T-cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101313061A (zh) * 2005-11-18 2008-11-26 大学健康网络 扩增双阴性t细胞的方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy;Merims S et al;《Leukemia》;20110513;第25卷(第9期);1-8 *
In vivo characterization of human double negatve T cells as a potential novel immunotherapy for AML;Li X et al;《CYTOTHERAPY》;20130430;第15卷(第4期);S41 *
Li X et al.In vivo characterization of human double negatve T cells as a potential novel immunotherapy for AML.《CYTOTHERAPY》.2013,第15卷(第4期), *
Li Zhang et al.Novel immunotherapy for AML using DNT cells.《The Journal of Immunology》.2013,第190卷(第1 supplement期), *
Merims S et al.Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.《Leukemia》.2011,第25卷(第9期), *
Novel immunotherapy for AML using DNT cells;Li Zhang et al;《The Journal of Immunology》;20130501;第190卷(第1 supplement期);1 *
Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells;Wilhelm M et al;《J Transl Med》;20140215;第12卷;1-5 *
Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells;Pigneux A et al;《Experimental Hematology》;20081231;第36卷(第12期);1648-1659 *

Also Published As

Publication number Publication date
CA2994462A1 (en) 2016-02-18
JP2017527551A (ja) 2017-09-21
US10517937B2 (en) 2019-12-31
ES2869624T3 (es) 2021-10-25
EP3180011B1 (en) 2021-03-17
CN107073039A (zh) 2017-08-18
EP3180011A1 (en) 2017-06-21
CA2994462C (en) 2023-12-19
JP6802150B2 (ja) 2020-12-16
WO2016023134A1 (en) 2016-02-18
US20170274060A1 (en) 2017-09-28
EP3180011A4 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
Lamb et al. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Liu et al. NK cell-based cancer immunotherapy: from basic biology to clinical development
Shimasaki et al. NK cells for cancer immunotherapy
US10912797B2 (en) Tumor infiltrating lymphocytes and methods of therapy
Locatelli et al. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies
EP2613801B1 (en) Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
CN107073039B (zh) 用于癌症治疗的免疫疗法
EP2663332B1 (en) Enhancement of allogeneic hematopoietic stem cell transplantation
JP7105188B2 (ja) 幹細胞移植方法
US20210008110A1 (en) Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
O’Neal et al. Traversing the bench to bedside journey for iNKT cell therapies
CA2942214C (en) Combination therapy with double negative t-cells
US20240122986A1 (en) Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
CN114729314A (zh) 用于癌症治疗的组合癌症疗法和细胞因子控制疗法
Singh et al. Natural killer cell-based Immunotherapy for Solid tumors: A Comprehensive Review
Kumar Singh et al. Natural killer cell-based Immunotherapy for Solid tumors: A Comprehensive Review Iran J Blood Cancer. 2025 June 30; 17 (2): 83-98
Low et al. Immune cell selection and isolation
Zhao et al. The progress of research on chimeric antigen receptor NK cells
AU2015268727B2 (en) Enhancement of allogeneic hematopoietic stem cell transplantation
Tonecka et al. Immune cells as targets and tools for cancer therapy
Cany et al. Decitabine enhances targeting of AML cells by CD34+ stem and progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice
HK1187528B (en) Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant